It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna will … Read more
This year’s powerful rally has more than made up for the carnage of 2022 on Wall Street. Tech stocks reasserted their leadership and even some out-of-favor sectors perked up in recent weeks. So, what about 2024 for the market and our Club stocks? The Federal Reserve remains a big question as milder inflation data and … Read more
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a … Read more
Ford Motor ‘s decision to cut production of its electric pick-up allows the automaker to refocus its strategy around its highly profitable hybrid vehicles, which in turn should boost its underperforming stock. Ford said Monday it’s cutting in half planned production of its all-electric F-150 Lightning pick-up truck next year due to moderating consumer demand. … Read more
Wall Street analysts are warming up to Coterra Energy , a stock we bought more shares of just last week when it was firmly out of favor. In recent days, Citigroup, UBS and Wells Fargo all upgraded Coterra to buy-equivalent ratings, highlighting a host of fundamental reasons — including improving capital efficiency — to own … Read more
Starbucks is facing multiple challenges in major markets both internationally and in the U.S., making shareholders like us wonder if it’s a good idea to sell shares before the company’s next earnings report, which is expected in late January. “Starbucks is what I call a tough own right now,” Jim Cramer said Tuesday during the … Read more
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled … Read more
